Hva nå, Vistin?
Kursen har siste tiden gått uforholdsmessig mye uten at noen informasjon er gitt. Et mindre innsidekjøp er i så måte av mindre betydning. Nå stiller jeg det spekulative spørsmålet om noe er på gang? Emisjon for å målbære visjonære planer, oppkjøp eller fusjon? Eller kanskje bare at fremdriftsplanen for nytt produksjonsanlegg er i rute eller blir forsert. Noe er på gang kan det se ut som. Morgendagen blir spennende. Videre ferd opp, eller falle litt tilbake, det gjenstår å se! For ikke å si høre.
Redigert 21.01.2021 kl 08:35
Du må logge inn for å svare
Svar kommer, så snart jeg får tid .....
d12m
23.04.2021 kl 08:30
1246
Vistin Pharma ASA: First quarter 2021 financial results
Oslo, Norway, 23(rd) of April 2021
Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN) today announces the financial results for the first quarter 2021
Vistin Pharma delivers another strong quarter with 15% increase in revenue YoY. Q1'21 revenue ended at MNOK 70.8 (Q1'20: MNOK 61.4).
First quarter EBITDA for pharmaceuticals was MNOK 16.3 (Q1'20: MNOK 14.2) a 15% increase compared to similar quarter last year
The net profit for the group ended at MNOK 8.8 (Q1'20: negative MNOK 168) for the first quarter of 2021. The net loss in Q1'20 was driven by closing of the oil derivative contracts.
Vistin Pharma had cash of MNOK 85 (Q1'20 MNOK: 317) as of 31 March 2021. Approx. 35% of the Metformin Expansion Project (MEP) has been paid as of March. The company has a strong balance sheet with an equity ratio of 86% and no interest-bearing debt.
The Fikkjebakke plant has been running at full capacity an achieved an all-time high production volume in the quarter driven by full effect of the 2nd reactor installed in Q3/Q4'20
Oslo, Norway, 23(rd) of April 2021
Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN) today announces the financial results for the first quarter 2021
Vistin Pharma delivers another strong quarter with 15% increase in revenue YoY. Q1'21 revenue ended at MNOK 70.8 (Q1'20: MNOK 61.4).
First quarter EBITDA for pharmaceuticals was MNOK 16.3 (Q1'20: MNOK 14.2) a 15% increase compared to similar quarter last year
The net profit for the group ended at MNOK 8.8 (Q1'20: negative MNOK 168) for the first quarter of 2021. The net loss in Q1'20 was driven by closing of the oil derivative contracts.
Vistin Pharma had cash of MNOK 85 (Q1'20 MNOK: 317) as of 31 March 2021. Approx. 35% of the Metformin Expansion Project (MEP) has been paid as of March. The company has a strong balance sheet with an equity ratio of 86% and no interest-bearing debt.
The Fikkjebakke plant has been running at full capacity an achieved an all-time high production volume in the quarter driven by full effect of the 2nd reactor installed in Q3/Q4'20
Blackwhite
23.04.2021 kl 08:44
1220
Mange dyktige bidragsytere på denne tråden. Hvorfor ikke lage en ny tråd? "Hva nå, Vistin" er liksom ikke dekkende for det som har vært, og ser ut til å bli en superinvestering for mange.
Nå vil f.eks. "What's next, Vistin" passe bedre. 💥Dette ser ut å bli nok en sterk børsdag, og jeg er spent på hvor det bringer kursen.....
Nå vil f.eks. "What's next, Vistin" passe bedre. 💥Dette ser ut å bli nok en sterk børsdag, og jeg er spent på hvor det bringer kursen.....